Estrogenic and neuroprotective properties of scutellarin from erigeron breviscapus: A drug against postmenopausal symptoms and alzheimer's disease

Planta Medica

Volumn 75, Issue 14, 2009, Pages 1489-1493

  Zhu, Judy T T ^a   Choi, Roy C Y ^a   Li, Jun ^a   Xie, Heidi Q H ^a   Bi, Cathy W C ^a   Cheung, Anna W H ^a   Dong, Tina T X ^a   Jiang, Zhi Y ^b   Chen, Ji J ^b   Tsim, Karl W K ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b KUNMING INSTITUTE OF BOTANY   (China)

Author keywords

Amyloid; Erigeron breviscapus Compositae; Estrogen; Neuroprotection; Scutellarin

Indexed keywords

AMYLOID BETA PROTEIN; ERIGERON BREVISCAPUS EXTRACT; ESTROGEN RECEPTOR ALPHA; FLAVONE DERIVATIVE; SCUTELLARIN;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL DEATH; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; ERIGERON; ESTROGEN ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDICINAL PLANT; MENOPAUSAL SYNDROME; NERVE CELL; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APIGENIN; CELL DEATH; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ERIGERON; ESTROGEN RECEPTOR ALPHA; GLUCURONIC ACIDS; HUMANS; NEUROPROTECTIVE AGENTS; PC12 CELLS; PHOSPHORYLATION; PHYTOESTROGENS; PHYTOTHERAPY; PLANT EXTRACTS; POSTMENOPAUSE; RATS;

ASTERACEAE; ERIGERON BREVISCAPUS;

EID: 73349094325     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1185776     Document Type: Article

References (20)

1. Glazier M G., Bowman M A. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med 2001 161 1161-1172
2. Bren L. The estrogen and progestin dilemma: new advice, labeling guidelines. FDA Consum 2003 37 10-11
3. Brinton L A., Brogan D R., Coates R J., Swanson C A., Potischman N, Stanford J L. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause 1998 15 145-151
4. Henderson V W., Paganini-Hill A, Miller B L., Elble R J., Reyes P F., Shoupe D, McCleary C A., Klein R A., Hake A M., Farlow M R. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000 54 295-301
5. Amantea D, Russo R, Bagetta G, Corasaniti M T. From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens. Pharmacol Res 2005 52 119-132
6. Tanzi R E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005 120 545-555
7. Miksicek R J. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 1993 44 37-43
8. Zhu J T., Choi R C., Chu G K., Cheung A W., Gao Q T., Li J, Jiang Z Y., Dong T T., Tsim K W. Flavonoids possess neuroprotective effects on cultured pheochromocytoma PC12 cells: a comparison of different flavonoids in activating estrogenic effect and in preventing beta-amyloid-induced cell death. J Agric Food Chem 2007 55 2438-2445
9. Zhang H F., Hu X M., Wang L X., Xu S Q., Zeng F D. Protective effects of scutellarin against cerebral ischemia in rats: evidence for inhibition of the apoptosis-inducing factor pathway. Planta Med 2009 75 121-126
10. Lin L L., Liu A J., Yu X H., Qin L P., Su D F. Protective effects of scutellarin and breviscapine on brain and heart ischemia in rat. J Cardiovasc Pharmacol 2005 50 327-332
11. Jin M, Jin F, Zhang L, Chen Z, Huang H. Two estrogen replacement therapies differentially regulate expression of estrogen receptors alpha and beta in the hippocampus and cortex of ovariectomized rat. Brain Res Mol Brain Res 2005 142 107-114
12. Hall J M., McDonnell D P. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 2005 5 343-357
13. Watson C S., Alyea R A., Hawkins B E., Thomas M L., Cunningham K A., Jakubas A A. Estradiol effects on the dopamine transporter-protein levels, subcellular location, and function. J Mol Signal 2006 1 5-5
14. Wakeling A E. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 2000 7 17-28
15. Singh M, Arseneault M, Sanderson T, Murthy V, Ramassamy C. Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem 2008 56 4855-4873
16. Gafner S, Bergeron C, Batcha L L., Angerhofer C K., Sudberg S, Sudberg E M., Guinaudeau H, Gauthier R. Analysis of Scutellaria lateriflora and its adulterants Teucrium canadense and Teucrium chamaedrys by LCUV/MS, TLC, and digital photomicroscopy. J AOAC Int 2003 86 453-460
17. Hong H, Liu G Q. Protection against hydrogen peroxide-induced cytotoxicity in PC12 cells by scutellarin. Life Sci 2004 74 2959-2973
18. Li X L., Li Y Q., Yan W M., Li H Y., Xu H, Zheng X X., Guo D W., Tang L K. A study of the cardioprotective effect of breviscapine during hypoxia of cardiomyocytes. Planta Med 2004 70 1039-1044
19. Raz L, Khan M M., Mahesh V B., Vadlamudi R K., Brann D W. Rapid estrogen signaling in the brain. Neurosignals 2008 16 140-153
20. Brinton R D. Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: recent insights and remaining challenges. Learn Mem 2001 8 121-133